|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
135,531,000 |
Market
Cap: |
298.17(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.47 - $3.22 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Xeris Biopharma Holdings is a pharmaceutical company. Co.'s primary focus is on therapies for patient populations in endocrinology, neurology, and gastroenterology. Co.'s products include: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages two years and older; Keveyis, the U.S. Food and Drug Administration approved therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev (levoketoconazole), a cortisol synthesis inhibitor used for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shannon John Patrick Jr |
See Remarks |
|
2020-05-08 |
4 |
B |
$3.20 |
$25,219 |
D/D |
7,886 |
95,493 |
2.74 |
96% |
|
Edick Paul R |
See Remarks |
|
2020-05-08 |
4 |
B |
$3.00 |
$99,000 |
D/D |
33,000 |
401,134 |
2.81 |
96% |
|
Hecht Beth |
See Remarks |
|
2020-03-13 |
4 |
B |
$1.97 |
$7,880 |
D/D |
4,000 |
57,083 |
2.74 |
23% |
|
Deutsch Barry M. |
See Remarks |
|
2020-02-14 |
4 |
B |
$4.15 |
$40,002 |
D/D |
9,639 |
39,359 |
2.74 |
-33% |
|
Edick Paul R |
See Remarks |
|
2020-02-14 |
4 |
B |
$4.15 |
$83,000 |
D/D |
20,000 |
183,134 |
2.81 |
-33% |
|
Shannon John Patrick Jr |
See Remarks |
|
2020-02-14 |
4 |
B |
$4.15 |
$49,999 |
D/D |
12,048 |
22,607 |
2.74 |
-33% |
|
Hecht Beth |
See Remarks |
|
2020-02-14 |
4 |
B |
$4.15 |
$16,600 |
D/D |
4,000 |
8,083 |
2.74 |
-33% |
|
Johnson Kenneth Erland |
See Remarks |
|
2020-02-14 |
4 |
B |
$4.15 |
$10,002 |
D/D |
2,410 |
6,115 |
2.74 |
-33% |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
436,824 |
|
- |
|
Edick Paul R |
See Remarks |
|
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
185,000 |
368,134 |
|
- |
|
Shannon John Patrick Jr |
See Remarks |
|
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
87,607 |
|
- |
|
Deutsch Barry M. |
See Remarks |
|
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
89,359 |
|
- |
|
Johnson Kenneth Erland |
See Remarks |
|
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
26,115 |
|
- |
|
Hecht Beth |
See Remarks |
|
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
53,083 |
|
- |
|
Edick Paul R |
See Remarks |
|
2020-01-31 |
4 |
D |
$6.37 |
$62,432 |
D/D |
(9,801) |
163,134 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2020-01-13 |
4 |
AS |
$5.50 |
$54,992 |
D/D |
(10,000) |
421,824 |
|
-18% |
|
Johnson Kenneth Erland |
See Remarks |
|
2019-12-31 |
4 |
A |
$5.99 |
$1,713 |
D/D |
286 |
3,705 |
|
- |
|
Hecht Beth |
See Remarks |
|
2019-12-31 |
4 |
A |
$5.99 |
$2,749 |
D/D |
459 |
4,083 |
|
- |
|
Shannon John Patrick Jr |
See Remarks |
|
2019-12-31 |
4 |
A |
$5.99 |
$2,624 |
D/D |
438 |
10,559 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2019-11-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
17,500 |
431,824 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2019-10-11 |
4 |
AS |
$7.97 |
$79,746 |
D/D |
(10,000) |
449,324 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2019-07-11 |
4 |
AS |
$12.04 |
$120,395 |
D/D |
(10,000) |
459,324 |
|
- |
|
Hecht Beth |
See Remarks |
|
2019-07-01 |
4 |
A |
$9.72 |
$10,925 |
D/D |
1,124 |
3,928 |
|
- |
|
Shannon John Patrick Jr |
See Remarks |
|
2019-07-01 |
4 |
A |
$9.72 |
$11,061 |
D/D |
1,138 |
10,121 |
|
- |
|
Deutsch Barry M. |
See Remarks |
|
2019-07-01 |
4 |
A |
$9.72 |
$13,880 |
D/D |
1,428 |
29,720 |
|
- |
|
83 Records found
|
|
Page 2 of 4 |
|
|